L’Oréal and Micreos announced today the signature of a license agreement to join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Under the terms […]
Europe does not have a clear or harmonized regulatory framework on probiotics, and therefore decisions may be made on them by individual Member States. The general view by both European and National authorities is that […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a […]
Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, […]
MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program. The grant will support the development of a […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. […]
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential […]
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli […]
Arranta Bio (“Arranta”), a leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to […]
Chr. Hansen Holding A/S (“Chr. Hansen”) has entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oligosaccharides (“HMO”) market The […]